Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 14/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24519809 | 1.00 | LMNA (0.59) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL21032675 | 0.84 | LMNA (0.61) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL30168945 | 0.84 | LMNA (0.61) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL3603190 | 0.84 | LMNA (0.61) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL23360714 | 0.84 | LMNA (0.61) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL5054816 | 0.84 | LMNA (0.61) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL12813284 | 0.81 | LGMN (0.44) | LMNAMAPTRECQLPKMALDH1A1 | |
| SCHEMBL26151071 | 0.80 | MAPT (0.43) | LMNAMAPTRECQLALDH1A1SMN1; SMN2 | |
| SCHEMBL2445796 | 0.80 | LMNA (0.75) | LMNAMAPTSIRT6RECQLPKM | |
| SCHEMBL31000475 | 0.79 | MAPT (0.52) | LMNAMAPTALDH1A1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694060-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | University of Utah Research Foundation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8569511-B2 | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569511-B2 | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569511-B2 | Substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-11-01 | — | — | US | disclosed |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-11-01 | — | — | US | disclosed |
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2012-11-01 | — | — | US | disclosed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135799-A1 | SUBSTITUTED 3-(1H-BENZO{D}IMIDAZOL-2-YL)-1H-INDAZOLE-ANALOGS AS INHIBITORS OF THE PDK1 KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277229-A1 | SUBSTITUTED 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-INDAZOLE ANALOGS AS INHIBITORS OF THE PDK1 KINASE | PDK1, PDK3, PDK2 | LMNA 2842/4885MAPT 2008/4885SIRT6 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.